Published in Clinical Trials Week, April 5th, 2004
PAH "is a progressive disease that, without treatment, ultimately results in right heart failure and death," scientists in Ireland explained. "For the majority of patients with advanced PAH, therapy requires cumbersome drug delivery devices with serious side effects."
"Endothelin, a potent endogenous vasoconstrictor, is increased in individuals with PAH," noted D. O'Callaghan and colleagues at University College Dublin. "The development of bosentan, a novel, well-tolerated, orally active endothelin antagonist, has significantly changed the therapeutic approach to PAH."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.